Indoco Remedies Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Revenue from operations stood at Rs 471.83 crore in the second quarter of FY26, up 9.59% as against Rs 430.66 crore posted in Q2 FY25.

The company reported a pre-tax loss of Rs 13.35 crore in Q2 FY26, compared with a pre-tax loss of Rs 4.84 crore in Q2 FY25. The firm also recorded exceptional items amounting to Rs 0.53 crore during the quarter.

EBITDA for the quarter stood at Rs 53.4 crore, compared with Rs 52.9 crore in the corresponding quarter of the previous year.

Aditi Panandikar, MD, Indoco Remedies, said, ?International formulation and API businesses had a good growth this quarter. The India formulation business performance was impacted due to revision in the GST rates. We are confident of regaining momentum in the coming quarters.

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company?s turnover is US$ 180 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.

Shares of Indoco Remedies fell 1.72% to currently trade at Rs 268.50 on the BSE.

Powered by Capital Market - Live News

Net Loss of Indoco Remedies reported to Rs 7.93 crore in the quarter ended September 2025 as against net loss of Rs 9.57 crore during the previous quarter ended September 2024. Sales rose 9.56% to Rs 471.83 crore in the quarter ended September 2025 as against Rs 430.66 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 6 November 2025.

Powered by Capital Market - Live News

Indoco Remedies has entered into a Sale Agreement and Lease Agreement on 29 August 2025 for sale and lease back of part of the Company's movable properties at its Waluj Facility located at B-19 MIDC, Waluj, Aurangabad, Maharashtra ? 431136 (Waluj Facility) and AnaCipher Clinical Research Organisation located at 2nd, 3rd & 4th Floor, Mirrakamshetty Mall, Opp. Doordarshan Bhavan, Ramanthapur Medchal-Malkajgiri District, Hyderabad - 500013, Telangana (CRO) on the terms and conditions as mentioned therein.

The sale of the aforesaid movable properties will not have any impact on the manufacturing or business of the Company, as the Company will continue to use the said movable properties on lease basis.

Powered by Capital Market - Live News